Compare BLFS & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLFS | SDGR |
|---|---|---|
| Founded | 1987 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.5M | 925.8M |
| IPO Year | 2013 | 2020 |
| Metric | BLFS | SDGR |
|---|---|---|
| Price | $21.91 | $13.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $32.00 | $21.00 |
| AVG Volume (30 Days) | 326.0K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.27 | 45.14 |
| EPS | ★ 0.02 | N/A |
| Revenue | $96,214,000.00 | ★ $255,869,000.00 |
| Revenue This Year | $19.73 | $0.76 |
| Revenue Next Year | $17.82 | $4.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 16.97 | ★ 23.29 |
| 52 Week Low | $17.86 | $10.95 |
| 52 Week High | $29.57 | $27.63 |
| Indicator | BLFS | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 56.20 | 59.98 |
| Support Level | $21.35 | $11.08 |
| Resistance Level | $26.14 | $13.33 |
| Average True Range (ATR) | 1.03 | 0.72 |
| MACD | 0.10 | 0.14 |
| Stochastic Oscillator | 68.35 | 86.24 |
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.